Results for tag: "Xtandi"

Xtandi is a drug used to treat prostate cancer. It is a type of androgen receptor inhibitor, which works by blocking the action of male hormones that can cause the growth of prostate cancer cells. Xtandi is used to treat metastatic castration-resistant prostate cancer (mCRPC) in men who have already received medical or surgical treatments to lower testosterone levels. It is also used to treat non-metastatic castration-resistant prostate cancer (nmCRPC) in men who have not received prior treatments to lower testosterone levels. Xtandi is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2012. It is currently the only FDA-approved androgen receptor inhibitor for the treatment of prostate cancer. Xtandi is marketed by Astellas Pharma, a Japanese pharmaceutical company, and is distributed in the US by Medivation, a subsidiary of Pfizer. Other companies involved in the market include Johnson & Johnson, Sanofi, and Bayer. Show Less Read more